Article
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.
The pharmacogenomics journal - 1 Jul 2017
Mahurkar S, Moldovan M, Suppiah V, Sorosina M, Clarelli F, Liberatore G, Malhotra S, Montalban X, Antigüedad A, Krupa M, Jokubaitis V G, McKay F C, Gatt P N, Fabis-Pedrini M J, Martinelli V, Comi G, Lechner-Scott J, Kermode A G, Slee M, Taylor B V, Vandenbroeck K, Comabella M, Boneschi F M, King C
Abstract excerpt
Up to 50% of multiple sclerosis (MS) patients do not respond to interferon-beta (IFN-β) treatment and determination of response requires lengthy clinical follow-up of up to 2 years. Response predictive genetic markers would significantly improve disease management. We aimed to identify IFN-β treatment response genetic marker(s) by performing a two-stage genome-wide association study (GWAS). The GWAS was carried...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.